JY BioMed Co., Ltd. is proud to announce the publication of its latest research in the internationally renowned journal Cancer Letters, highlighting a novel antibody-drug conjugate (ADC) platform targeting CEACAM6 for the treatment of aggressive cancers, including brain metastases.